Precision treatment in advanced hepatocellular carcinoma

被引:90
|
作者
Yang, Xupeng [1 ,2 ]
Yang, Chen [3 ,4 ]
Zhang, Shu [1 ,2 ]
Zhu, Andrew X. [5 ,6 ]
Geng, Haigang [3 ]
Bernards, Rene [7 ]
Qin, Wenxin [3 ]
Fan, Jia [1 ]
Wang, Cun [3 ]
Gao, Qiang [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat,Key Lab Carcinogene, Shanghai, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Key Lab Med Epigenet & Metab, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Syst Med Canc, Shanghai 200032, Peoples R China
[4] German Canc Res Ctr, Immune Regulat Canc Grp, Heidelberg, Germany
[5] I Mab Biopharm, Shanghai, Peoples R China
[6] Jiahui Int Canc Ctr, Jiahui Hlth, Shanghai, Peoples R China
[7] Netherlands Canc Inst, Oncode Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands
关键词
PATIENT-DERIVED ORGANOIDS; 1ST-LINE TREATMENT; MOLECULAR CLASSIFICATION; OPEN-LABEL; NEOANTIGEN VACCINE; TARGETED THERAPY; NON-INFERIORITY; GROWTH-FACTOR; DOUBLE-BLIND; SORAFENIB;
D O I
10.1016/j.ccell.2024.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the unique molecular characteristics of individual patient to personalize treatment modalities, aiming to maximize therapeutic efficacy while minimizing side effects. Although precision treatment has shown significant success in multiple cancer types, its application in HCC remains in its infancy. In this review, we discuss key aspects of precision treatment in HCC, including therapeutic biomarkers, molecular classifications, and the heterogeneity of the tumor microenvironment. We also propose future directions, ranging from revolutionizing current treatment methodologies to personalizing therapy through functional assays, which will accelerate the next phase of advancements in this area.
引用
收藏
页码:180 / 197
页数:18
相关论文
共 50 条
  • [1] Treatment of advanced hepatocellular carcinoma
    Forner, Alejandro
    Rodriguez De Lope, Carlos
    Reig, Maria
    Bruix, Jordi
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (06): : 461 - 468
  • [2] Systemic Treatment for Advanced Hepatocellular Carcinoma
    Bouattour, Mohamed
    Mehta, Neil
    He, Aiwu R.
    Cohen, Emil, I
    Nault, Jean-Charles
    LIVER CANCER, 2019, 8 (05) : 341 - 358
  • [3] Antineoplaston treatment for advanced hepatocellular carcinoma
    Kumabe, T
    Tsuda, H
    Uchida, M
    Ogoh, Y
    Hayabuchi, N
    Sata, M
    Nakashima, O
    Hara, H
    ONCOLOGY REPORTS, 1998, 5 (06) : 1363 - 1367
  • [4] Treatment of Large and Advanced Hepatocellular Carcinoma
    Eddie K. Abdalla
    Alban Denys
    Kiyoshi Hasegawa
    Thomas W. T. Leung
    Masatoshi Makuuchi
    Ravi Murthy
    Dario Ribero
    Daria Zorzi
    Jean-Nicolas Vauthey
    Guido Torzilli
    Annals of Surgical Oncology, 2008, 15 : 979 - 985
  • [5] The Treatment Landscape of Advanced Hepatocellular Carcinoma
    Wong, Kit Man
    King, Gentry G.
    Harris, William P.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (07) : 917 - 927
  • [6] The Treatment Landscape of Advanced Hepatocellular Carcinoma
    Kit Man Wong
    Gentry G. King
    William P. Harris
    Current Oncology Reports, 2022, 24 : 917 - 927
  • [7] Sorafenib for the treatment of advanced hepatocellular carcinoma
    Connock, M.
    Round, J.
    Bayliss, S.
    Tubeuf, S.
    Greenheld, W.
    Moore, D.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 17 - 21
  • [8] Multidisciplinary Treatment of Advanced Hepatocellular Carcinoma
    Yang, Zhe
    Abdrakhimov, Bulat
    Wang, Shuo
    Xie, Qin-Fen
    Zheng, Shu-Sen
    CASE REPORTS IN GASTROENTEROLOGY, 2020, 14 (01) : 98 - 102
  • [9] Treatment of large and advanced hepatocellular carcinoma
    Abdalla, Eddie K.
    Denys, Alban
    Hasegawa, Kiyoshi
    Leung, Thomas W. T.
    Makuuchi, Masatoshi
    Murthy, Ravi
    Ribero, Dario
    Zorzi, Daria
    Vauthey, Jean-Nicolas
    Torzilli, Guido
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (04) : 979 - 985
  • [10] Capecitabine for treatment of advanced hepatocellular carcinoma
    von Delius, S.
    Lersch, C.
    Mayr, M.
    Stock, K.
    Schulte-Frohlinde, E.
    Schmid, R. M.
    Eckel, F.
    HEPATO-GASTROENTEROLOGY, 2007, 54 (80) : 2310 - 2314